Insights into multidrug-resistant K. pneumoniae urinary tract infections: From susceptibility to mortality

被引:23
|
作者
Miftode, Ionela-Larisa [1 ]
Nastase, Eduard Vasile [1 ]
Miftode, Radu-Stefan [2 ]
Miftode, Egidia Gabriela [1 ]
Iancu, Luminita Smaranda [3 ]
Lunca, Catalina [3 ]
Paduraru, Dana-Teodora Anton [4 ]
Costache, Irina-Iuliana [2 ]
Stafie, Celina-Silvia [3 ]
Dorneanu, Olivia-Simona [3 ]
机构
[1] Gr T Popa Univ Med & Pharm, Fac Med, Dept Infect Dis Internal Med 2, 16 Univ St, Iasi 700115, Romania
[2] Gr T Popa Univ Med & Pharm, Fac Med, Dept Cardiol Internal Med 1, 16 Univ St, Iasi 700115, Romania
[3] Gr T Popa Univ Med & Pharm, Fac Med, Dept Prevent Med & Interdisciplinar, Iasi 700115, Romania
[4] Gr T Popa Univ Med & Pharm, Fac Med, Dept Mother & Child Med, Iasi 700115, Romania
关键词
ESBL-producing; K; pneumoniae; susceptibility; risk factors; antibiotics; SPECTRUM BETA-LACTAMASES; BLOOD-STREAM INFECTIONS; RISK-FACTORS; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; ANTIMICROBIAL SUSCEPTIBILITY; ENTEROBACTERIACEAE; IMPACT; COMMUNITY; PREVALENCE;
D O I
10.3892/etm.2021.10520
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The incidence of urinary tract infections (UTIs) caused by Klebsiella pneumoniae has exhibited an increasing trend and has become a high burden for many public health systems, especially in hospital settings. Multidrug resistance associated with the production of extended-spectrum beta-lactamases (ESBL) among K. pneumoniae isolates is endemic in Southeastern Europe. We retrospectively analyzed 75 cases admitted to 'St. Parascheva' Clinical Hospital of Infectious Diseases in Iasi, Romania, during the first 6 months of 2019 (January 1 to June 30), who had a confirmed diagnosis of K. pneumoniae UTI at discharge. From a total of 75 patients, 34 (45.3%) presented ESBL+ K. pneumoniae. The mean age was 66 years (70.1 for the ESBL+ patients vs. 62.6 for the ESBL- patients, P=0.0365). There was a symmetrical sex distribution (37 men vs. 38 women). Of these, 22 men had ESBL+ K. pneumoniae UTIs, compared to only 15 with an ESBL- strain, P=0.0087. Another risk factor for ESBL+ K. pneumoniae UTIs was the presence of hospitalization in the past 6 months; 20 (58.82%) patients with ESBL+ infections were previously hospitalized, compared to only 5 (12.19%) patients with ESBL- strains, P<0.0001. The urinary catheter carriers presented an increased prevalence of ESBL+ infections (15/34 vs. 5/41, P=0.0012). Regarding mortality, ESBL+ infections caused 6 fatalities, compared to only 1 death in the ESBL- group, P=0.0166. ESBL+ K. pneumoniae strains represent an important cause of healthcare-related UTIs, with a significantly higher mortality rate compared to ESBL- strains. Early identification and adequate management of the risk factors incriminated in ESBL+ UTIs should be a priority for physicians in order to limit the dissemination of the ESBL-producing strains and thus to improve the outcome of these patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria
    George G. Zhanel
    Marianna Pozdirca
    Alyssa R. Golden
    Courtney K. Lawrence
    Sheryl Zelenitsky
    Liam Berry
    Frank Schweizer
    Denice Bay
    Heather Adam
    Michael A. Zhanel
    Philippe Lagacé-Wiens
    Andrew Walkty
    Neal Irfan
    Kurt Naber
    Joseph P. Lynch
    James A. Karlowsky
    Drugs, 2022, 82 : 533 - 557
  • [32] Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections
    Linsenmeyer, Katherine
    Strymish, Judith
    Gupta, Kalpana
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7593 - 7596
  • [33] Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group
    Manges, AR
    Johnson, JR
    Foxman, B
    O'Bryan, TT
    Fullerton, KE
    Riley, LW
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14): : 1007 - 1013
  • [34] Multidrug-resistant Streptococcus pneumoniae infections -: Current and future therapeutic options
    Van Bambeke, Françoise
    Reinert, Rene R.
    Appelbaum, Peter C.
    Tulkens, Paul M.
    Peetermans, Willy E.
    DRUGS, 2007, 67 (16) : 2355 - 2382
  • [35] Multidrug-resistant organism infections and mortality: estimates from a large Italian hospital
    Moro, M.
    Vigezzi, G. P.
    Callari, E.
    Biancardi, A.
    Nizzero, P.
    Cichero, P.
    Signorelli, C.
    Odone, A.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30
  • [36] Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review
    Brust, K.
    Evans, A.
    Plemmons, R.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (10) : 2606 - 2610
  • [37] In Vitro Activity of Fosfomycin on Multidrug-Resistant Strains of Klebsiella pneumoniae and Klebsiella oxytoca Causing Urinary Tract Infection
    Fatemeh Ghayaz
    Fatemeh Zeynali Kelishomi
    Samira Amereh
    Ehsan Aali
    Amir Javadi
    Amir Peymani
    Farhad Nikkhahi
    Current Microbiology, 2023, 80
  • [38] In Vitro Activity of Fosfomycin on Multidrug-Resistant Strains of Klebsiella pneumoniae and Klebsiella oxytoca Causing Urinary Tract Infection
    Ghayaz, Fatemeh
    Kelishomi, Fatemeh Zeynali
    Amereh, Samira
    Aali, Ehsan
    Javadi, Amir
    Peymani, Amir
    Nikkhahi, Farhad
    CURRENT MICROBIOLOGY, 2023, 80 (04)
  • [39] Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales
    Bouiller, Kevin
    Zayet, Souheil
    Lalloz, Paul-Emile
    Potron, Anais
    Gendrin, Vincent
    Chirouze, Catherine
    Klopfenstein, Timothee
    ANTIBIOTICS-BASEL, 2022, 11 (02):
  • [40] Phages as potential life-saving therapeutic option in the treatment of multidrug-resistant urinary tract infections
    Zalewska-Piatek, Beata
    Nagorka, Michalina
    ACTA BIOCHIMICA POLONICA, 2025, 72